Kolkata, West Bengal -- (SBWIRE) -- 09/05/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Mitcham Industries, Inc.(NASDAQ:MIND), Fastenal Company(NASDAQ:FAST), Shares of POZEN Inc.(NASDAQ:POZN), Agenus Inc(NASDAQ:AGEN).
Mitcham Industries, Inc.(NASDAQ:MIND) slumps to three-month lows after posting a Q2 loss as equipment leasing revenue declined for the fourth straight quarter.Soft Q2 results were expected due to seasonal patterns in the leasing business, but "the level of leasing revenues was clearly disappointing," CEO Bill Mitcham said, citing continued weakness in U.S. land activity, project delays due to permitting difficulties, and labor unrest and security issues in Colombia.Revenue in the equipment leasing segment fell 41% to $6.4M; gross margin fell to 20.6% from 32.1%.
Can Traders Buy MIND After The Solid Rally? Get Free Trend Analysis Here
Fastenal Company(NASDAQ:FAST) moves up after posting solid August sales numbers. Net sales rose 2.5% year over year to $297M, up from $290M in the same month of 2012.Daily sales were $13M, up 7.2% from $12.6M in 2012.Manufacturing customers grew 6.1% Non-residential construction customers grew 7.3%.The change in currencies in foreign countries, primarily Canada, reduced daily sales growth rate by 0.3% during the month.Barron's points out the strong numbers, noting that Wunderlich feels the numbers indicate growing demand.
Should Investors Buy FAST After Yesterday’s Slump? Find Out Here
Shares of POZEN Inc.(NASDAQ:POZN) post double-digit gains.The company announced a partnership with Sanofi (SNY) yesterday for the commercialization of PA8140 and PA32540 (safer aspirin). SA contributor and Zacks analyst Jason Napodano sees PA as a "$500M product worldwide" and based on the disclosed terms of the deal, Napodano says the shares may be worth $9 each.
How Should Investors Trade POZN After The Recent Volatility? Get Free Trend Analysis Here
Shares of Agenus Inc(NASDAQ:AGEN) collapse after GlaxoSmithKline (GSK -0.9%) says the MAGE A-3 cancer vaccine missed one of its primary endpoints in a Phase 3 melanoma trial.MAGE A-3 uses AGEN's QS-21 as an adjuvant. Shareholders will now look to MAGRIT data (the non-small cell lung cancer trial for MAGE-A3) due in H1 2014.
Should Investors Buy AGEN After Yesterday’s Slump? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)